# Innate and Adaptive Immunity in Rheumatic Disease

## Introduction

Rheumatic diseases represent a broad and clinically diverse spectrum of immune dysregulation involving both the innate and adaptive arms of the immune system. A sophisticated understanding of immunopathogenesis is foundational for rational therapeutic selection, as the targets of modern biologic and small-molecule therapies are rooted directly in the molecular and cellular mechanisms that drive these diseases. The translational advances of the past three decades have been extraordinary, yielding more than twenty targeted therapies in rheumatology since the approval of the first tumor necrosis factor inhibitor in 1998. This chapter provides a comprehensive overview of the immunologic underpinnings of the major rheumatic diseases, highlighting the key pathways that have been successfully targeted by current therapeutics and those that represent emerging opportunities for intervention.

## Innate Immune System in Rheumatic Disease

### Pattern Recognition Receptors (PRRs)

The innate immune system relies on germline-encoded pattern recognition receptors to detect conserved molecular structures associated with pathogens and tissue damage. In rheumatic diseases, aberrant activation of these receptors by endogenous ligands -- so-called damage-associated molecular patterns (DAMPs) -- is a critical driver of chronic inflammation.

Toll-like receptors (TLRs) represent one of the best-characterized families of PRRs implicated in autoimmune rheumatic disease. TLR7 and TLR9, which are located within endosomal compartments, recognize endogenous nucleic acids and are particularly important in the pathogenesis of systemic lupus erythematosus (SLE). Impaired clearance of apoptotic debris allows self-derived DNA and RNA to access endosomal TLRs, triggering sustained type I interferon production. The recent identification of gain-of-function TLR7 variants, such as the Y264H mutation, which causes a monogenic form of lupus, has provided definitive genetic evidence for the pathogenic role of this pathway.

NOD-like receptors (NLRs) serve as intracellular sensors of danger signals and play a pivotal role in inflammasome biology. The NLRP3 inflammasome, in particular, is activated by a wide range of stimuli including monosodium urate crystals in gout, calcium pyrophosphate crystals in pseudogout, and constitutively in the monogenic autoinflammatory syndromes such as cryopyrin-associated periodic syndromes (CAPS) and familial Mediterranean fever (FMF). Upon activation, the NLRP3 inflammasome drives the processing and secretion of interleukin-1 beta (IL-1beta) and IL-18, both of which are potent mediators of neutrophilic inflammation.

The cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING) pathway represents a more recently characterized mechanism of innate immune activation. This cytosolic DNA-sensing pathway drives type I interferon production and has been implicated in SLE, STING-associated vasculopathy with onset in infancy (SAVI), and Aicardi-Goutieres syndrome. DAMP signaling through other receptors, including S100 proteins (S100A8/A9), high-mobility group box 1 (HMGB1), and uric acid crystals, activates innate immunity through TLR2 and TLR4, further amplifying inflammatory cascades in multiple rheumatic conditions.

### Neutrophils and NETosis

Neutrophils, long considered mere bystanders in chronic autoimmune inflammation, are now recognized as active contributors to disease pathogenesis through a process known as NETosis. Neutrophil extracellular traps (NETs) are web-like structures composed of decondensed chromatin studded with antimicrobial proteins that are extruded from activated neutrophils. While NETs serve a physiologic role in pathogen trapping, their inappropriate release or impaired clearance exposes a rich repertoire of autoantigens, including double-stranded DNA, histones, myeloperoxidase (MPO), and proteinase 3 (PR3). This process is particularly relevant to the pathogenesis of SLE, ANCA-associated vasculitis, and rheumatoid arthritis (RA). Impaired clearance of NETs, as occurs with DNase I deficiency, perpetuates autoimmune activation by allowing prolonged exposure of nuclear and cytoplasmic autoantigens to the immune system. A distinct subset of neutrophils known as low-density granulocytes (LDGs), which are enriched in the peripheral blood of patients with SLE, are particularly prone to NET formation and produce excessive quantities of type I interferon, further amplifying the interferon signature that characterizes active lupus.

### Monocytes and Macrophages

Monocytes and macrophages are central effector cells of the innate immune system that play critical roles across the spectrum of rheumatic diseases. The traditional M1 (classically activated, pro-inflammatory) versus M2 (alternatively activated, anti-inflammatory and tissue-remodeling) polarization paradigm, while oversimplified and not fully reflective of the plasticity and heterogeneity of macrophage phenotypes in vivo, remains a clinically useful framework for understanding their contributions to disease.

In rheumatoid arthritis, expansion of macrophages in the synovial sublining layer is one of the most robust histologic correlates of disease activity, and the degree of sublining macrophage infiltration has emerged as a potential biomarker for therapeutic response. In dermatomyositis, CD163-positive macrophages accumulate in both skin and muscle tissue, contributing to local inflammation and tissue damage. At the extreme end of macrophage-driven pathology lies macrophage activation syndrome (MAS), a life-threatening complication of several rheumatic diseases characterized by uncontrolled macrophage and T-cell activation, hemophagocytosis, and a cytokine storm involving massive elevations of interferon-gamma, IL-18, and other pro-inflammatory mediators.

### Complement System

The complement system is a critical effector arm of innate immunity that bridges innate and adaptive immune responses and plays a central role in the pathogenesis of several rheumatic diseases. The classical pathway, initiated by C1q binding to immune complexes, is particularly relevant to SLE, where deficiency of early classical pathway components confers striking susceptibility to disease. Deficiency of C1q, the most upstream component, is the strongest single-gene risk factor for SLE, with more than 90 percent of affected individuals developing the disease. This is thought to relate to impaired clearance of apoptotic material, which in turn leads to the accumulation of nuclear autoantigens and the perpetuation of autoimmune responses.

The alternative pathway, which is activated through spontaneous low-level C3 hydrolysis and amplifies complement activation regardless of the initiating trigger, is dysregulated in atypical hemolytic uremic syndrome (aHUS) through mutations in regulatory proteins such as Factor H. The lectin pathway, initiated by mannose-binding lectin (MBL) recognition of carbohydrate patterns on pathogens, is less directly implicated in autoimmunity but contributes to infection susceptibility when deficient. Terminal complement activation, culminating in the formation of the membrane attack complex (C5-9), is a key effector mechanism in anti-glomerular basement membrane disease and other immune complex-mediated conditions; this pathway is the target of eculizumab, a monoclonal antibody against C5 that prevents MAC formation.

<image>A detailed diagram of the innate immune system components involved in rheumatic disease, showing pattern recognition receptors (TLRs, NLRs, cGAS-STING) on cell surfaces and intracellularly, with arrows pointing to downstream signaling cascades (NF-kB, type I IFN, inflammasome activation). Include neutrophils undergoing NETosis releasing web-like DNA structures, macrophages in M1/M2 states, and the complement cascade (classical, alternative, lectin pathways) converging on C3 and the membrane attack complex. Use a clean medical illustration style with labeled components.</image>

## Adaptive Immune System in Rheumatic Disease

### T Cell Biology

The adaptive immune system provides antigen-specific immune responses through T and B lymphocytes, and its dysregulation is central to the pathogenesis of virtually all autoimmune rheumatic diseases. CD4-positive T helper cells differentiate into functionally distinct subsets under the influence of specific cytokine environments, each contributing to different aspects of rheumatic disease pathology.

T helper 1 (Th1) cells, which produce interferon-gamma and tumor necrosis factor-alpha under the direction of the transcription factor T-bet, predominate in the rheumatoid synovium and drive macrophage activation and granulomatous inflammation. Th2 cells, characterized by IL-4, IL-5, and IL-13 production and GATA3 expression, are the dominant effectors in eosinophilic granulomatosis with polyangiitis (EGPA), where they drive eosinophilic tissue infiltration. The Th17 subset, which produces IL-17A, IL-17F, and IL-22 under the control of the transcription factor RORgammat, has emerged as critically important in the spondyloarthropathies, psoriatic arthritis, and rheumatoid arthritis, and represents the target of several approved biologic therapies.

T follicular helper (Tfh) cells, identified by expression of CXCR5, ICOS, and IL-21, reside in germinal centers where they provide critical help for B cell maturation, class switching, and autoantibody production. Their expanded presence in SLE drives the pathogenic germinal center reactions that produce the diverse array of autoantibodies characteristic of the disease. Regulatory T cells (Tregs), characterized by FOXP3 expression and high-level CD25 surface expression, serve as essential guardians of peripheral tolerance. Defective Treg number or function has been documented in SLE, RA, and juvenile idiopathic arthritis, and therapeutic strategies aimed at expanding the Treg compartment, including low-dose IL-2 therapy, are under active investigation.

CD8-positive cytotoxic T lymphocytes contribute to tissue damage in the inflammatory myopathies, where they invade non-necrotic muscle fibers in polymyositis and inclusion body myositis. Gamma-delta T cells, an unconventional T cell subset enriched at mucosal surfaces and entheseal sites, may play an initiating role in spondyloarthritis pathogenesis through IL-17 production in response to mechanical stress and microbial signals.

### B Cell Biology

B cells contribute to rheumatic disease pathology through multiple mechanisms, including autoantibody production, antigen presentation, and cytokine secretion. B cell development proceeds through a series of well-defined stages from pro-B cells in the bone marrow through immature and transitional stages to mature, memory, and ultimately plasma cell differentiation. Critical tolerance checkpoints exist at both the central (bone marrow) and peripheral levels to eliminate self-reactive B cells; defects at these checkpoints have been demonstrated in both SLE and RA, allowing autoreactive B cells to escape deletion and contribute to disease.

The diverse array of autoantibodies produced by self-reactive B cells defines much of the diagnostic and prognostic landscape of rheumatology. Rheumatoid factor and anti-citrullinated protein antibodies (anti-CCP) characterize seropositive RA; antinuclear antibodies (ANA), anti-double-stranded DNA, and anti-Smith antibodies are hallmarks of SLE; and anti-neutrophil cytoplasmic antibodies (ANCA) define the ANCA-associated vasculitides. B cell activating factor (BAFF, also known as BLyS) is a TNF family cytokine that is critical for B cell survival and maturation and is elevated in SLE, providing the rationale for belimumab, an anti-BAFF monoclonal antibody approved for lupus treatment.

Beyond antibody production, B cells serve as potent antigen-presenting cells and produce pro-inflammatory cytokines including IL-6 and TNF-alpha, contributing to disease pathology through antibody-independent mechanisms. Long-lived plasma cells, which reside in protective bone marrow niches, are resistant to B cell depletion therapy with rituximab, explaining why autoantibody levels may persist despite effective peripheral B cell depletion.

### MHC and Antigen Presentation

The major histocompatibility complex (MHC), encoded by the human leukocyte antigen (HLA) gene complex, governs antigen presentation and represents the strongest genetic risk factor for most autoimmune rheumatic diseases. HLA-B27, a class I MHC molecule, is the strongest genetic association in spondyloarthritis, present in approximately 90 percent of patients with ankylosing spondylitis compared to only 8 percent of the general population. The mechanisms by which HLA-B27 predisposes to disease remain an area of active investigation, with leading hypotheses including misfolding of the B27 heavy chain, formation of cell-surface homodimers, and presentation of arthritogenic peptides.

The HLA-DRB1 shared epitope (SE), defined by the amino acid motifs QKRAA or QRRAA at positions 70-74 of the DRB1 molecule, is the strongest genetic risk factor for seropositive rheumatoid arthritis. The shared epitope influences the binding groove of the MHC class II molecule, favoring the presentation of citrullinated peptides to CD4-positive T cells. This process is intimately linked to post-translational modification of proteins by peptidylarginine deiminase (PAD) enzymes, which convert arginine residues to citrulline. Citrullinated peptides are preferentially presented by shared epitope-bearing HLA alleles, triggering the anti-CCP autoimmune response that is the immunologic hallmark of seropositive RA. HLA-DRB1*15:01 has been associated with SLE susceptibility, further underscoring the central role of antigen presentation in autoimmune disease pathogenesis.

<image>A comprehensive illustration of T helper cell differentiation from a naive CD4+ T cell, showing branching pathways to Th1, Th2, Th17, Tfh, and Treg subsets. Each branch should show the polarizing cytokines (e.g., IL-12 for Th1, IL-6+TGF-beta for Th17), key transcription factors (T-bet, GATA3, RORgammat, Bcl-6, FOXP3), effector cytokines produced, and the rheumatic diseases each subset drives. Include a central APC presenting antigen via MHC II to the naive T cell. Use color coding for each subset.</image>

## Cytokine Networks in Rheumatic Disease

### Pro-inflammatory Cytokines

Cytokines are the signaling molecules that orchestrate immune responses, and their dysregulated production or signaling is a defining feature of rheumatic disease pathology. Tumor necrosis factor-alpha (TNF-alpha) occupies a central position in the cytokine network driving rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Produced primarily by macrophages, T cells, and fibroblast-like synoviocytes, TNF-alpha promotes synovial inflammation, osteoclast activation, and cartilage destruction, and its therapeutic blockade was the first successful application of targeted biologic therapy in rheumatology.

Interleukin-6 is a pleiotropic cytokine with systemic effects that extend far beyond the joint. It drives hepatic production of acute phase reactants including C-reactive protein and serum amyloid A, promotes Th17 differentiation and B cell maturation, and is elevated in RA, giant cell arteritis, and Castleman disease. The IL-1 family, including IL-1 alpha and IL-1 beta, plays a dominant role in crystal arthropathies, adult-onset Still disease, familial Mediterranean fever, and the cryopyrin-associated periodic syndromes. IL-17A, produced by Th17 cells, type 3 innate lymphoid cells, and gamma-delta T cells, is the principal driver of enthesitis and axial inflammation in the spondyloarthropathies and is a therapeutic target of secukinumab and ixekizumab. IL-23, which acts upstream of the Th17 axis, is critical for the maintenance and expansion of Th17 cells and drives the IL-23/IL-17 axis that is central to psoriatic arthritis and spondyloarthritis pathogenesis.

Type I interferons, particularly interferon-alpha and interferon-beta, are the signature cytokines of systemic lupus erythematosus. An interferon gene expression signature, measured by composite interferon gene scores, is present in approximately 50 percent of SLE patients and correlates with disease activity, providing the rationale for anifrolumab, an anti-type I interferon receptor antibody. Interferon-gamma, the sole type II interferon, drives Th1 responses and macrophage activation and is characteristically elevated in macrophage activation syndrome.

### Anti-inflammatory Cytokines

The immune system maintains homeostasis through anti-inflammatory cytokines that counterbalance pro-inflammatory signals. IL-10 is a key regulatory cytokine produced by multiple cell types, and its deficiency leads to exaggerated colitis and arthritis in animal models. Transforming growth factor-beta (TGF-beta) has complex, context-dependent effects: it drives fibrosis in systemic sclerosis while also promoting both Treg and Th17 differentiation depending on the accompanying cytokine milieu. IL-37 and IL-38, emerging members of the IL-1 superfamily, have demonstrated anti-inflammatory properties in preclinical models and may represent future therapeutic targets.

| T Helper Subset | Transcription Factor | Key Cytokines Produced | Polarizing Cytokine | Rheumatic Disease Association | Therapeutic Target |
|----------------|---------------------|----------------------|--------------------|-----------------------------|-------------------|
| Th1 | T-bet | IFN-gamma, TNF-alpha | IL-12 | RA (synovium), granulomatous inflammation | TNF inhibitors |
| Th2 | GATA3 | IL-4, IL-5, IL-13 | IL-4 | EGPA (eosinophilic infiltration) | Mepolizumab (anti-IL-5) |
| Th17 | RORgammat | IL-17A, IL-17F, IL-22 | IL-6 + TGF-beta | SpA, PsA, RA | Secukinumab, ixekizumab (anti-IL-17) |
| Tfh | Bcl-6 | IL-21 | IL-6, IL-21 | SLE (germinal center reactions, autoantibody production) | Belimumab (anti-BAFF, indirect) |
| Treg | FOXP3 | IL-10, TGF-beta | TGF-beta + IL-2 | Defective in SLE, RA, JIA | Low-dose IL-2 (under investigation) |

### JAK-STAT Signaling

The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is the intracellular signaling cascade utilized by a wide array of cytokine receptors. Understanding which JAK pairs are engaged by specific cytokines is essential for predicting both the therapeutic effects and side effects of JAK inhibitors. JAK1 and JAK2 together mediate signaling downstream of interferon-alpha, interferon-beta, interferon-gamma, IL-6, IL-12, and IL-23. JAK1 and JAK3 pair to transduce signals from gamma-chain cytokines including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, which are critical for lymphocyte development and function. JAK2 and TYK2 cooperate to mediate IL-12 and IL-23 signaling, and selective TYK2 inhibition by deucravacitinib targets this pathway in psoriatic arthritis with a potentially more favorable safety profile. The clinical JAK inhibitors currently approved for rheumatic diseases include tofacitinib (JAK1/3), baricitinib (JAK1/2), and upadacitinib (JAK1-selective), each with distinct cytokine inhibition profiles that inform their clinical applications.

## Autoimmunity Mechanisms

### Breaking Tolerance

The development of autoimmune disease requires the breakdown of immunologic tolerance, the normally robust system of safeguards that prevents the immune system from mounting destructive responses against self-antigens. This process involves the convergence of genetic susceptibility, epigenetic modifications, and environmental triggers. More than 200 genetic risk loci have been identified for rheumatoid arthritis alone, and polygenic risk scores that integrate these variants are emerging as tools for disease prediction. Epigenetic modifications, including DNA hypomethylation in CD4-positive T cells in SLE and histone modifications that alter gene expression without changing the DNA sequence, contribute to the dysregulation of immune gene expression in autoimmune disease.

Environmental triggers play a critical role in disease initiation. Cigarette smoking promotes citrullination of proteins in the lungs through activation of PAD enzymes, generating the citrullinated antigens that drive anti-CCP antibody production in genetically susceptible individuals carrying the shared epitope. Silica exposure, Epstein-Barr virus (EBV) infection, and periodontal disease caused by Porphyromonas gingivalis, which produces its own PAD enzyme, have all been implicated as environmental triggers. Molecular mimicry, in which microbial antigens share structural homology with self-antigens, and epitope spreading, in which the initial immune response to a single autoantigen expands to encompass additional self-targets, are fundamental mechanisms by which localized immune activation can evolve into systemic autoimmunity.

### The Mucosal Origins Hypothesis

A paradigm-shifting concept in rheumatoid arthritis pathogenesis is the mucosal origins hypothesis, which proposes that autoimmune responses may originate at mucosal surfaces, particularly the lung, oral cavity, and gut, years before the onset of clinical joint disease. This hypothesis is supported by several lines of evidence. Anti-CCP antibodies have been detected in sputum samples before they appear in serum, suggesting that the initial anti-citrullinated protein immune response may be generated in the bronchial mucosa. Periodontal disease caused by P. gingivalis, which possesses a bacterial PAD enzyme capable of citrullinating host proteins, is epidemiologically associated with RA risk. Gut dysbiosis, with enrichment of Prevotella copri in the intestinal microbiome, has been observed in early RA. Collectively, these observations suggest a model in which environmental exposures at mucosal surfaces trigger citrullination and anti-citrullinated protein immune responses in genetically susceptible individuals, with a prolonged preclinical phase of mucosal and systemic autoimmunity preceding the onset of clinical arthritis.

<image>A flowchart illustrating the mucosal origins hypothesis of rheumatoid arthritis. Start with environmental triggers (smoking, periodontal disease, gut dysbiosis) at mucosal surfaces. Show citrullination by PAD enzymes at mucosal sites, presentation of citrullinated peptides by HLA-DRB1 shared epitope alleles to T cells, B cell activation and anti-CCP antibody production, followed by transition from mucosal to systemic autoimmunity, and finally synovial inflammation with pannus formation. Include a timeline showing pre-clinical phase (years) before clinical arthritis onset.</image>

## Immune Mechanisms by Disease

### Rheumatoid Arthritis

The immunopathology of rheumatoid arthritis centers on the synovial joint, where a complex interplay of innate and adaptive immune cells drives chronic inflammation and progressive joint destruction. Fibroblast-like synoviocytes (FLS) in the rheumatoid synovium acquire an aggressive, quasi-neoplastic phenotype, characterized by anchorage-independent growth, resistance to apoptosis, and the ability to invade cartilage. The resulting pannus -- a hyperplastic, highly vascularized synovial tissue -- directly erodes cartilage and bone at the cartilage-pannus junction. Osteoclastogenesis, driven by the RANKL/RANK/OPG axis and amplified by TNF-alpha and IL-6, leads to the characteristic marginal bone erosions that are the radiographic hallmark of the disease. Immune complexes containing rheumatoid factor and anti-CCP antibodies activate complement and Fc receptors within the joint, further perpetuating the inflammatory cycle.

### Systemic Lupus Erythematosus

The immunopathogenesis of SLE is characterized by a fundamental defect in the clearance of apoptotic cells, which exposes nuclear autoantigens to the immune system and drives a cascade of autoimmune activation. Plasmacytoid dendritic cells, activated by nucleic acid-containing immune complexes through endosomal TLR7 and TLR9, produce massive quantities of type I interferon, which amplifies the activation of both innate and adaptive immune cells. Loss of T and B cell tolerance leads to the production of a remarkable diversity of autoantibodies, including antibodies against double-stranded DNA, nucleosomes, and ribonucleoprotein complexes. These autoantibodies form immune complexes that deposit in kidneys, skin, and other organs, activating complement and driving tissue damage through Fc receptor-mediated inflammation.

### Spondyloarthritis

The pathogenesis of spondyloarthritis is distinguished from that of RA and SLE by its strong association with HLA-B27, its predilection for entheseal and axial structures, and the central role of the IL-23/IL-17 axis. HLA-B27 misfolding in the endoplasmic reticulum triggers the unfolded protein response, which promotes IL-23 production by macrophages. The IL-23/IL-17 axis drives entheseal and axial inflammation through activation of tissue-resident immune cells at mechanically stressed sites. Mechanical stress at entheses, which serve as the primary sites of disease initiation, triggers innate immune activation independently of adaptive immunity. Subclinical gut inflammation, detected histologically in 50 to 60 percent of patients with ankylosing spondylitis, reflects the intimate connection between mucosal immunity and the pathogenesis of spondyloarthritis.

## Key Clinical Pearls

- C1q deficiency is the strongest single-gene risk factor for SLE (>90% penetrance)
- The shared epitope (HLA-DRB1) predisposes to seropositive erosive RA, not seronegative RA
- NETosis is a shared pathogenic mechanism across SLE, ANCA vasculitis, gout, and RA
- JAK-STAT pathway knowledge predicts which cytokines each JAKi will affect and helps anticipate side effects
- The mucosal origins hypothesis explains why smoking is a risk factor specifically for anti-CCP-positive RA
- Low-dose IL-2 therapy is under investigation to selectively expand Tregs in SLE and other autoimmune diseases

<image>A comparative table-style illustration showing the dominant immune mechanisms in five major rheumatic diseases (RA, SLE, SpA, vasculitis, crystal arthropathies). For each disease, depict the key cell types involved, dominant cytokines, autoantibodies (if any), and the targeted therapy that blocks each pathway. Use icons for cells and arrows for cytokine signaling, with drug names annotated at their points of action. Clean, educational medical diagram style.</image>

## References
1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219.
2. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110-2121.
3. Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46(2):183-196.
4. Crow MK. Type I interferon in the pathogenesis of lupus. J Immunol. 2014;192(12):5459-5468.
5. Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374(26):2563-2574.